Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2025
Institutional positions in Inhibrx Biosciences, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 92
- −6 vs. Q4 2024
- Shares held
- 10.8M
- −243.7K (−2.2%) vs. Q4 2024
- Total value
- $151.0M
- −$19.0M (−11.2%) vs. Q4 2024
- New holders
- 9
- 18 more added
- Sold out
- 15
- 36 more reduced
3 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −248−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −222−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −146−100.0% | Sold out |
| Huntington National Bank | 0 | $0 | 0.00% | −90−100.0% | Sold out |
| Measured Risk Portfolios, Inc. | 0 | $0 | 0.00% | −37−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Cigogne Management SA | – | – | – | – | Not filed |
| Wetherby Asset Management Inc | – | – | – | – | Not filed |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |